KPT-330 is a CRM1-selective inhibitor of nuclear export (SINE) that inhibits protein trafficking from the nucleus. KPT-330 displays anticancer chemotherapeutic activity. In mesothelioma cells, this compound inhibits cell growth and induces G1 phase cell cycle arrest and apoptosis; in vivo, it suppresses tumor growth.
| Cas No. | 1421923-86-5 |
|---|---|
| Purity | ≥99% |
| Formula | C17H11F6N7O |
| Formula Wt. | 443.31 |
| IUPAC Name | (2Z)-3-{3-[3,5-Bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-N'-(2-pyrazinyl)acrylohydrazide |
| Synonym | Selinexor |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | K6276 Info Sheet PDF |
|---|
Ishizawa J, Kojima K, Hail N Jr, et al. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 2015 Jun 3. [Epub ahead of print]. PMID: 26048327.
De Cesare M, Cominetti D, Doldi V, et al. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget. 2015 May 30;6(15):13119-32. PMID: 25948791.
Parikh K, Cang S, Sekhri A, et al. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol. 2014 Oct 15;7:78. PMID: 25316614.
